EC OKs Roche's MS med Ocrevus [Seeking Alpha]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Seeking Alpha
EC OKs Roche's MS med OcrevusThe European Commission (EC)approves Roche's (OTCQX:RHHBY) OCREVUS (ocrelizumab) for the treatment of patients with active relapsing forms of multiple sclerosis (MS) and patients with early primary progressive MS.Ocrelizumab, a humanized monoclonal antibody targeting CD20-positive B cells, is administered once every six months via intravenous infusion.OCREVUS was previously approved in the U.S., Canada and Australia.Click to subscribe to real-time analytics on RHHBYNow read:Roche Obtains FDA Approval For Hemophilia A Drug, Time To Push Shire Out »
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Xaira, an AI drug discovery startup, launches with a massive $1B, says it's ‘ready' to start developing drugs [TechCrunch]TechCrunch
- Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Swiss pharmaceutical maker Roche says group sales dropped 6% [Yahoo! Finance]Yahoo! Finance
- Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology [Yahoo! Finance]Yahoo! Finance